Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 102

1.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.

J Am Heart Assoc. 2017 May 22;6(5). pii: e004987. doi: 10.1161/JAHA.116.004987.

2.

Perceived stress and smoking-related behaviors and symptomatology in male and female smokers.

Lawless MH, Harrison KA, Grandits GA, Eberly LE, Allen SS.

Addict Behav. 2015 Dec;51:80-3. doi: 10.1016/j.addbeh.2015.07.011. Epub 2015 Jul 26.

3.

Morbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in project Phidisa.

Maduna PH, Dolan M, Kondlo L, Mabuza H, Dlamini JN, Polis M, Mnisi T, Orsega S, Maja P, Ledwaba L, Molefe T, Sangweni P, Malan L, Matchaba G, Khabo P, Grandits G, Neaton JD.

PLoS One. 2015 Apr 9;10(4):e0121843. doi: 10.1371/journal.pone.0121843. eCollection 2015.

4.

Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Lifson AR, Grandits GA, Gardner EM, Wolff MJ, Pulik P, Williams I, Burman WJ; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:88-96. doi: 10.1111/hiv.12237.

5.

Covariate-adjusted measures of discrimination for survival data.

White IR, Rapsomaniki E; Emerging Risk Factors Collaboration.

Biom J. 2015 Jul;57(4):592-613. doi: 10.1002/bimj.201400061. Epub 2014 Dec 20.

6.

Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals.

Young LC, Roediger MP, Grandits G, Baker J, Somboonwit C, Williams I, Lundgren JD, Neaton JD, Soliman EZ.

Biomark Med. 2014;8(9):1073-83. doi: 10.2217/bmm.14.27.

7.

Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study.

Dawood FZ, Roediger MP, Grandits G, Miller D, Fisher M, Zhang ZM, Hodder S, Hoy JF, Lundgren JD, Neaton JD, Soliman EZ; INSIGHT SMART Study Group.

J Electrocardiol. 2014 Mar-Apr;47(2):264-71. doi: 10.1016/j.jelectrocard.2013.12.001. Epub 2013 Dec 4.

8.

Assessing risk prediction models using individual participant data from multiple studies.

Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM; Emerging Risk Factors Collaboration.

Am J Epidemiol. 2014 Mar 1;179(5):621-32. doi: 10.1093/aje/kwt298. Epub 2013 Dec 22.

9.

The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis.

Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, Kaptoge S, Whitlock G, Qiao Q, Lewington S, Di Angelantonio E, Vander Hoorn S, Lawes CM, Ali MK, Mozaffarian D, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group; Asia-Pacific Cohort Studies Collaboration (APCSC); Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE); Emerging Risk Factor Collaboration (ERFC); Prospective Studies Collaboration (PSC).

PLoS One. 2013 Jul 30;8(7):e65174. doi: 10.1371/journal.pone.0065174. Print 2013.

10.

Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial.

Stamler J, Neaton JD, Cohen JD, Cutler J, Eberly L, Grandits G, Kuller LH, Ockene J, Prineas R; MRFIT Research Group.

J Am Heart Assoc. 2012 Oct;1(5):e003640. doi: 10.1161/JAHA.112.003640. Epub 2012 Oct 25.

11.

Marine recruit adherence in a skin and soft tissue infection prevention trial: implications for recruit research and public health application.

Schlett CD, Grandits GA, Millar EV, Whitman TJ, Tribble DR.

Mil Med. 2012 Nov;177(11):1335-42.

PMID:
23198510
12.

Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.

Saul SM, Duprez DA, Zhong W, Grandits GA, Cohn JN.

J Hum Hypertens. 2013 Jun;27(6):362-7. doi: 10.1038/jhh.2012.54. Epub 2012 Nov 29.

PMID:
23190794
13.

C-reactive protein, fibrinogen, and cardiovascular disease prediction.

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J.

N Engl J Med. 2012 Oct 4;367(14):1310-20. doi: 10.1056/NEJMoa1107477.

14.

Chlorhexidine does not select for resistance in Staphylococcus aureus isolates in a community setting.

Johnson MD, Schlett CD, Grandits GA, Mende K, Whitman TJ, Tribble DR, Hospenthal DR, Murray PR.

Infect Control Hosp Epidemiol. 2012 Oct;33(10):1061-3. doi: 10.1086/667744. No abstract available.

PMID:
22961032
15.

Skin and soft tissue infections among HIV-infected persons in the late combination antiretroviral therapy era.

Crum-Cianflone NF, Grandits G, Weintrob A, Ganesan A, Agan B, Landrum M.

Int J STD AIDS. 2012 Jul;23(7):507-11. doi: 10.1258/ijsa.2011.011360.

16.

The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.

Okulicz JF, Grandits GA, French JA, Perucca E, George JM, Landrum ML, Acosta EP, Birbeck GL.

Epilepsy Res. 2013 Feb;103(2-3):245-53. doi: 10.1016/j.eplepsyres.2012.07.009. Epub 2012 Jul 24.

17.

Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis.

Emerging Risk Factors Collaboration.

Int J Epidemiol. 2012 Oct;41(5):1419-33. doi: 10.1093/ije/dys086. Epub 2012 Jul 23.

18.

Chlorhexidine gluconate reduces transmission of methicillin-resistant Staphylococcus aureus USA300 among Marine recruits.

Whitman TJ, Schlett CD, Grandits GA, Millar EV, Mende K, Hospenthal DR, Murray PR, Tribble DR.

Infect Control Hosp Epidemiol. 2012 Aug;33(8):809-16. doi: 10.1086/666631. Epub 2012 Jun 11.

PMID:
22759549
19.

Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness.

Okulicz JF, Grandits GA, Dolan MJ, Marconi VC, Wortmann G, Landrum ML.

AIDS Res Ther. 2012 Apr 2;9:10. doi: 10.1186/1742-6405-9-10.

20.

Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study.

Tribble DR, Conger NG, Fraser S, Gleeson TD, Wilkins K, Antonille T, Weintrob A, Ganesan A, Gaskins LJ, Li P, Grandits G, Landrum ML, Hospenthal DR, Millar EV, Blackbourne LH, Dunne JR, Craft D, Mende K, Wortmann GW, Herlihy R, McDonald J, Murray CK.

J Trauma. 2011 Jul;71(1 Suppl):S33-42. doi: 10.1097/TA.0b013e318221162e. Review. No abstract available.

Supplemental Content

Loading ...
Support Center